Experienced in Waldenstrom Macroglobulinemia

Dr. Mitchell E. Horwitz

Infectious Disease | Oncology | Hematology
Duke Health
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
32 Years of Experience
Experienced in Waldenstrom Macroglobulinemia
Duke Health
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mitchell Horwitz is an Infectious Disease specialist and an Oncologist in Durham, North Carolina. Dr. Horwitz has been practicing medicine for over 32 years and is rated as an Experienced provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Oncology
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710
Call: 919-684-8111
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
Call: 919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
A Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
Enrollment Status: Recruiting
Publish Date: January 07, 2026
Intervention Type: Procedure, Biological
Study Drug: NRTX-1001
Study Phase: Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Biological
Study Phase: Phase 3
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease
A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: Glasdegib
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Enrollment Status: Terminated
Publish Date: January 30, 2020
Intervention Type: Biological
Study Phase: Phase 3
Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation
Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: February 13, 2018
Intervention Type: Biological
Study Phase: Phase 1
A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation
A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: June 05, 2017
Intervention Type: Biological
Study Phase: Phase 1
View 10 Less Clinical Trials

112 Total Publications

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025
View All 112 Publications
Similar Doctors
Distinguished in Waldenstrom Macroglobulinemia
Dr. Alexandra Stefanovic
Hematology Oncology | Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Alexandra Stefanovic
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English, French, German, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexandra Stefanovic is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Stefanovic is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Waldenstrom Macroglobulinemia, Diffuse Large B-Cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Stefanovic is currently accepting new patients.

Distinguished in Waldenstrom Macroglobulinemia
Dr. Christopher E. Dittus
Hematology Oncology | Emergency Medicine | Hematology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Christopher E. Dittus
Hematology Oncology | Emergency Medicine | Hematology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.5 miles away)
984-974-1000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Dittus is a Hematologist Oncology specialist and an Emergency Medicine provider in Chapel Hill, North Carolina. Dr. Dittus has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Dittus is currently accepting new patients.

Distinguished in Waldenstrom Macroglobulinemia
Dr. Kevin J. Lorentsen
Hematology Oncology | Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Kevin J. Lorentsen
Hematology Oncology | Hematology | Oncology

Wakemed Specialists Group LLC

23 Sunnybrook Rd, 
Raleigh, NC 
 (24.7 miles away)
919-350-6002
Languages Spoken:
English
See accepted insurances

Kevin Lorentsen is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Lorentsen is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Thrombocytopenia, Childhood Iron Deficiency Anemia, Subacute Combined Degeneration, and Iron Deficiency Anemia.

VIEW MORE WALDENSTROM MACROGLOBULINEMIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Horwitz's expertise for a condition
ConditionClose
    • Distinguished
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Horwitz is
      Distinguished
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Horwitz is
      Distinguished
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Chronic Graft Versus Host Disease (cGvHD)
      Dr. Horwitz is
      Distinguished
      . Learn about Chronic Graft Versus Host Disease (cGvHD).
      See more Chronic Graft Versus Host Disease (cGvHD) experts
    • Graft Versus Host Disease (GvHD)
      Dr. Horwitz is
      Distinguished
      . Learn about Graft Versus Host Disease (GvHD).
      See more Graft Versus Host Disease (GvHD) experts
    • Multiple Myeloma
      Dr. Horwitz is
      Distinguished
      . Learn about Multiple Myeloma.
      See more Multiple Myeloma experts
    • Myelodysplastic Syndrome (MDS)
      Dr. Horwitz is
      Distinguished
      . Learn about Myelodysplastic Syndrome (MDS).
      See more Myelodysplastic Syndrome (MDS) experts
    • Advanced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Horwitz is
      Advanced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Horwitz is
      Advanced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Angioimmunoblastic T-cell Lymphoma
      Dr. Horwitz is
      Advanced
      . Learn about Angioimmunoblastic T-cell Lymphoma.
      See more Angioimmunoblastic T-cell Lymphoma experts
    • Aplastic Anemia
      Dr. Horwitz is
      Advanced
      . Learn about Aplastic Anemia.
      See more Aplastic Anemia experts
    • Bone Marrow Transplant
      Dr. Horwitz is
      Advanced
      . Learn about Bone Marrow Transplant.
      See more Bone Marrow Transplant experts
    • Castleman Disease
      Dr. Horwitz is
      Advanced
      . Learn about Castleman Disease.
      See more Castleman Disease experts
    View All 22 Advanced Conditions
    • Experienced
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Horwitz is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Acute Myelomonocytic Leukemia
      Dr. Horwitz is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Adult T-Cell Leukemia
      Dr. Horwitz is
      Experienced
      . Learn about Adult T-Cell Leukemia.
      See more Adult T-Cell Leukemia experts
    • Agranulocytosis
      Dr. Horwitz is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anaplastic Large Cell Lymphoma
      Dr. Horwitz is
      Experienced
      . Learn about Anaplastic Large Cell Lymphoma.
      See more Anaplastic Large Cell Lymphoma experts
    • Anemia
      Dr. Horwitz is
      Experienced
      . Learn about Anemia.
      See more Anemia experts
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.